VFEND
Drug
PFIZER INC.
Total Payments
$217,651
Transactions
27
Doctors
17
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $26,123 | 3 | 0 |
| 2017 | $191,528 | 24 | 17 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $203,496 | 7 | 93.5% |
| Travel and Lodging | $8,349 | 3 | 3.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,500 | 5 | 1.6% |
| Consulting Fee | $2,063 | 1 | 0.9% |
| Food and Beverage | $242.59 | 11 | 0.1% |
Payments by Type
Research
$203,496
7 transactions
General
$14,155
20 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| MULTICENTER INTERNATIONAL RETROSPECTIVE STUDY ON EFFICACY OF DIAGNOSTIC DRIVEN PRIMARY THERAPY OF INVASIVE ASPERGILLOSIS IN HIGHRISK PATIENTS WITH HEMATOLOGIC MALIGNANCY OR STEM CELL TRANSPLANT USING NOVEL ANTIFUNGAL THERAPY | PFIZER INTERNATIONAL LLC | $107,373 | 0 |
| VORICONAZOLE VS AMPHOB IN EARLY TREATMENT OF ASPERGILLOSIS | PFIZER INC. | $45,000 | 0 |
| VFEND SPECIAL INVESTIGATION FOR PEDIATRIC | PFIZER INC. | $25,000 | 0 |
| EVALUATION OF AZOLE RESISTANCE OF MOLDS AT THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER | PFIZER INC. | $21,123 | 0 |
| INTERNATIONAL EXPERIENCE OF ANTIFUNGAL VORICONAZOLE CONTAINING REGIMENSCOMPARED TO AMPHOTERICIN B BASED THERAPY AS AN EARLY PREEMPTIVE ORDIAGNOSTIC DRIVEN PRIMARY THERAPY FOR INVASIVE ASPERGILLOSIS IN HIGHRISKPATIENTS | PFIZER INC. | $5,000 | 0 |
Top Doctors Receiving Payments for VFEND
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Houston, TX | $203,496 | 7 |
| , M.D | Infectious Disease | Houston, TX | $8,462 | 4 |
| , M.D | Pediatrics | Durham, NC | $2,063 | 1 |
| , M.D | Pulmonary Disease | Los Angeles, CA | $700.00 | 1 |
| , MD | Anesthesiology | San Francisco, CA | $700.00 | 1 |
| , MD | Infectious Disease | Pittsburgh, PA | $700.00 | 1 |
| , MD | Pulmonary Disease | Philadelphia, PA | $700.00 | 1 |
| , MD | Critical Care Medicine | San Antonio, TX | $700.00 | 1 |
| , D.O | Family Medicine | Bakersfield, CA | $16.76 | 1 |
| , MD | Internal Medicine | Northport, NY | $16.50 | 1 |
| , M.D | Family Medicine | Elizabethton, TN | $13.17 | 1 |
| , MD | Medical Genetics, Ph.D. Medical Genetics | Elizabethton, TN | $13.17 | 1 |
| , M.D | Family Medicine | Elizabethton, TN | $13.17 | 1 |
| , MD | Internal Medicine | Kansas City, MO | $11.43 | 1 |
| , MD | Family Medicine | Kansas City, MO | $11.43 | 1 |
| , D.O | Family Medicine | Kansas City, MO | $11.43 | 1 |
| , DO | Family Medicine | Kansas City, MO | $11.43 | 1 |
| , MD | Family Medicine | Kansas City, MO | $11.43 | 1 |
Ad
Manufacturing Companies
- PFIZER INTERNATIONAL LLC $117,898
- PFIZER INC. $99,753
Product Information
- Type Drug
- Total Payments $217,651
- Total Doctors 17
- Transactions 27
About VFEND
VFEND is a drug associated with $217,651 in payments to 17 healthcare providers, recorded across 27 transactions in the CMS Open Payments database. The primary manufacturer is PFIZER INC..
Payment data is available from 2017 to 2018. In 2018, $26,123 was paid across 3 transactions to 0 doctors.
The most common payment nature for VFEND is "Unspecified" ($203,496, 93.5% of total).
VFEND is associated with 5 research studies, including "MULTICENTER INTERNATIONAL RETROSPECTIVE STUDY ON EFFICACY OF DIAGNOSTIC DRIVEN PRIMARY THERAPY OF INVASIVE ASPERGILLOSIS IN HIGHRISK PATIENTS WITH HEMATOLOGIC MALIGNANCY OR STEM CELL TRANSPLANT USING NOVEL ANTIFUNGAL THERAPY" ($107,373).